Ön jelenleg a(z) Magyar Tudományos Akadémia Videotorium aloldalát böngészi. A keresési találatok, illetve az aloldal minden felülete (Főoldal, Kategóriák, Csatornák, Élő közvetítések) kizárólag az intézményi aloldal tartalmait listázza. Amennyiben a Videotorium teljes archívumát kívánja elérni, kérjük navigáljon vissza a Videotorium főoldalára!

Thematic Sessions IV. d. The Ethics of Regenerative Medicine

37

Thematic Sessions IV. d. The Ethics of Regenerative Medicine


Organised by:  European Academies Science Advisory Council (EASAC)
Venue: Hungarian Academy of Sciences, Reading Room
Abstract: 

Regenerative medicine comprises novel approaches such as cell and gene therapies aimed at tissue regeneration and repair. It offers significant future promise to tackle intractable diseases but, so far, has proved itself in only a few specific clinical indications, for example for haematopoietic and skin disorders.

 

In a current project conducted by EASAC and FEAM, the European academies of science and medicine are reviewing opportunities and challenges in this rapidly advancing field, what principles might be offered for guidance and what are the strategic priorities. A project focus is on stem cell therapy but conclusions may be generalisable to other regenerative medicine. In this session, we review progress with a particular emphasis on ethical considerations. While there are considerable scientific and clinical opportunities, there are also major concerns. First, an increasing problem worldwide of unregulated, unscrupulous clinics promising a wide range of benefits using poorly characterised stem cells with little evidence and vague rationale, with the intention of significant commercial gain. Secondly, premature marketing approval and commercialisation of approaches based on insufficient evidence as a result of evolving business models, encouraged by regulatory authority initiatives for accelerated access.

 

Ethical concerns for patient access to experimental treatments include: uncertainty about risk-benefit (safety and efficacy) when patients have few other options; lack of sufficient validated evidence for informed consent; problems of information supply by unvalidated sources (for example, on the internet); potential conflict of interest for medical professionals; and issues for equity and fairness, if treatment costs are substantial and when health service resources are diverted. Many of these concerns arise from knowledge gaps and there are implications for the responsibility of researchers and other stakeholders, including medical journals and regulators.

 

 
Moderator (confirmed):

    Volker ter Meulen, President, IAP

Speakers (confirmed):

    Robin Fears, Biosciences Programme Director, EASAC
    Göran Hermerén, Professor, Lund University, Department of Medical Ethics, BioMedical Centre
    Anne Cambon-Thomsen, Emeritus research director; member of UMR 1027 Inserm/ Univ Toulouse 3, CNRS & University of Toulouse
    Balázs Sarkadi, Professor emeritus, Research Centre for Natural Sciences
    Beáta Sperlágh, Professor, deputy director, Institute of Experimental Medicine
    Elisa Corritore, Forum Policy Officer, Federation of European Academies of Medicine (FEAM)

Rapporteur:

    Balázs Enyedi, Assistant Professor, Semmelweis University

Photo: 

https://flic.kr/s/aHsmJLHSu6

több kevesebb


World Science Forum 2019, Hungarian Academy of Sciences, Reading Room

Tudomány és társadalom

wsf2019

Dr. Prof. Volker ter Meulen (moderátor)
Dr. Prof. Sarkadi Balázs (előadó)
Sperlágh Beáta (előadó)
Dr. Robin Fears (előadó)
Prof. Göran Hermerén (előadó)
Prof. Anne Cambon-Thomsen (előadó)
Dr. Elisa Corritore (előadó)

1:33:24

2019. november 22.

Videotorium admin

2019. december 10.

37
<iframe width="480" height="385" src="//mta.videotorium.hu/hu/embed/35423" frameborder="0" allowfullscreen="allowfullscreen"></iframe>

Audió letöltés